PACIFIC BIOSCIENCES CALIF IN's ticker is PACB and the CUSIP is 69404D108. A total of 228 filers reported holding PACIFIC BIOSCIENCES CALIF IN in Q2 2022. The put-call ratio across all filers is 0.17 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9,416,980 | -37.2% | 1,127,782 | 0.0% | 0.05% | -37.9% |
| Q2 2023 | $14,999,501 | +14.9% | 1,127,782 | 0.0% | 0.09% | +22.5% |
| Q1 2023 | $13,059,716 | +41.6% | 1,127,782 | 0.0% | 0.07% | +29.1% |
| Q4 2022 | $9,225,257 | +40.9% | 1,127,782 | 0.0% | 0.06% | +27.9% |
| Q3 2022 | $6,547,000 | -72.8% | 1,127,782 | -79.3% | 0.04% | -68.6% |
| Q2 2022 | $24,067,000 | -51.4% | 5,444,963 | 0.0% | 0.14% | -51.9% |
| Q1 2022 | $49,549,000 | -55.5% | 5,444,963 | 0.0% | 0.28% | -47.4% |
| Q4 2021 | $111,404,000 | -19.9% | 5,444,963 | 0.0% | 0.54% | -11.3% |
| Q3 2021 | $139,119,000 | +24.2% | 5,444,963 | +70.1% | 0.61% | +24.2% |
| Q2 2021 | $111,973,000 | +5.0% | 3,201,972 | 0.0% | 0.49% | +6.5% |
| Q1 2021 | $106,658,000 | +28.4% | 3,201,972 | 0.0% | 0.46% | +47.6% |
| Q4 2020 | $83,059,000 | +158.9% | 3,201,972 | -1.5% | 0.31% | +144.5% |
| Q3 2020 | $32,078,000 | – | 3,250,000 | – | 0.13% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 2,660,000 | $24,206,000 | 11.49% |
| Data Collective II GP, LLC | 164,249 | $1,495,000 | 5.44% |
| Decheng Capital Management III (Cayman), LLC | 1,463,872 | $13,321,000 | 4.08% |
| SB Management Ltd | 1,886,107 | $17,164,000 | 3.33% |
| Casdin Capital, LLC | 7,990,652 | $72,715,000 | 3.26% |
| ORACLE INVESTMENT MANAGEMENT INC | 1,225,395 | $11,151,000 | 2.20% |
| Jackson Square Partners, LLC | 22,542,589 | $205,137,000 | 2.04% |
| BOURNE LENT ASSET MANAGEMENT INC | 556,865 | $5,067,000 | 1.59% |
| ARK Investment Management | 27,259,521 | $248,062,000 | 1.04% |
| Nikko Asset Management Americas, Inc. | 14,021,205 | $127,873,000 | 0.94% |